報價延遲最少15分鐘:2025/01/11 17:48 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.3 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.46/--
|
|
企業價值
156.25M
|
| 資產負債 |
|
每股賬面淨值
0.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, thatlead to tumor cell survival, growth, migration, and invasion. |